Induction of influenza matrix protein 1 and MelanA-specific T lymphocytes in vitro using mRNA-electroporated dendritic cells

Cancer Gene Therapy

Volumn 10, Issue 9, 2003, Pages 696-706

  Tuyaerts, Sandra ^a   Michiels, Annelies ^a   Corthals, Jurgen ^a   Bonehill, Aude ^a   Heirman, Carlo ^a   De Greef, Catherine ^a   Noppe, Sofie M ^a   Thielemans, Kris ^a  

^a VRIJE UNIVERSITEIT BRUSSEL   (Belgium)

Author keywords

Cancer; Dendritic cells; Immunotherapy; mRNA electroporation

Indexed keywords

CANCER VACCINE; CD4 ANTIGEN; INFLUENZA VIRUS MATRIX PROTEIN 1; INTERLEUKIN 12; MATRIX PROTEIN; MELAN A; MESSENGER RNA; PEPTIDE; TUMOR ANTIGEN; UNCLASSIFIED DRUG;

ARTICLE; CANCER IMMUNOTHERAPY; CONTROLLED STUDY; CRYOPRESERVATION; CYTOKINE PRODUCTION; CYTOTOXIC T LYMPHOCYTE; DENDRITIC CELL; DNA MODIFICATION; ELECTROPORATION; FREEZING; GENE EXPRESSION; HUMAN; HUMAN CELL; IMMUNE RESPONSE; IN VITRO STUDY; INFLUENZA VIRUS; MONOCYTE; NONHUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION; T LYMPHOCYTE; THAWING; TRANSGENE;

ANTIGEN PRESENTATION; ANTIGENS, CD40; ANTIGENS, NEOPLASM; CANCER VACCINES; CELL LINE; CELL SURVIVAL; CLINICAL TRIALS; CRYOPRESERVATION; DENDRITIC CELLS; ELECTROPORATION; HUMANS; IMMUNOLOGIC MEMORY; IMMUNOTHERAPY; INTERFERON TYPE II; INTERLEUKIN-12; NEOPLASM PROTEINS; ORTHOMYXOVIRIDAE; RNA, MESSENGER; T-LYMPHOCYTES; TRANSGENES; VIRAL MATRIX PROTEINS;

INFLUENZA VIRUS;

EID: 0141564862     PISSN: 09291903     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.cgt.7700622     Document Type: Article

References (44)

1. Steinman RM. The dendritic cell system and its role in immunogenicity. Annu Rev Immunol. 1991;9:271-296.
2. Cella M, Sallusto F, Lanzavecchia A. Origin, maturation and antigen presenting function of dendritic cells. Curr Opin Immunol. 1997;9:10-16.
3. Banchereau J, Steinman RM. Dendritic cells and the control of immunity. Nature. 1998;392:245-252.
4. Bell D, Young JW, Banchereau J. Dendritic cells. Adv Immunol. 1999;72:255-324.
5. Banchereau J, Briere F, Caux C, et al. Immunobiology of dendritic cells. Annu Rev Immunol. 2000;18:767-811.
6. Guermonprez P, Valladeau J, Zitvogel L, et al. Antigen presentation and T cell stimulation by dendritic cells. Annu Rev Immunol. 2002;20:621-667.
7. Celluzzi CM, Mayordomo JI, Storkus WJ, et al. Peptide-pulsed dendritic cells induce antigen-specific CTL-mediated protective tumor immunity. J Exp Med. 1996;183:283-287.
8. Pardoll DM. Cancer vaccines. Nat Med. 1998;4:525-531.
9. Brossart P, Wirths S, Stuhler G, et al. Induction of cytotoxic T-lymphocyte responses in vivo after vaccinations with peptide-pulsed dendritic cells. Blood. 2000;96:3102-3108.
10. Schlienger K, Craighead N, Lee P, et al. Efficient priming of protein antigen-specific human CD4(+) T cells by monocyte-derived dendritic cells. Blood. 2000;96:3490-3498.
11. Chen CH, Wu TC. Experimental vaccine strategies for cancer immunotherapy. J Biomed Sci. 1998;5:231-252.
12. Hung K, Hayashi R, Lafond-Walker A, et al. The central role of CD4(+) T cells in the antitumor immune response. J Exp Med. 1998;188:2357-2368.
13. Gao FG, Khammanivong V, Liu WJ, et al. Antigen-specific CD4+ T-cell help is required to activate a memory CD8+ T cell to a fully functional tumor killer cell. Cancer Res. 2002;62:6438-6441.
14. Pardoll DM, Topalian SL. The role of CD4+ T cell responses in antitumor immunity. Curr Opin Immunol. 1998;10:588-594.
15. Wang RF. The role of MHC class II-restricted tumor antigens and CD4+ T cells in antitumor immunity. Trends Immunol. 2001;22:269-276.
16. Marzo AL, Kinnear BF, Lake RA, et al. Tumor-specific CD4+ T cells have a major "post-licensing" role in CTL mediated anti-tumor immunity. J Immunol. 2000;165:6047-6055.
17. Tobery TW, Siliciano RF. Targeting of HIV-1 antigens for rapid intracellular degradation enhances cytotoxic T lymphocyte (CTL) recognition and the induction of de novo CTL responses in vivo after immunization. J Exp Med. 1997;185:909-920.
18. Tobery T, Siliciano RF. Cutting edge: induction of enhanced CTL-dependent protective immunity in vivo by N-end rule targeting of a model tumor antigen. J Immunol. 1999;162:639-642.
19. Varshavsky A, Turner G, Du F, et al. Felix Hoppe-Seyler Lecture 2000. The ubiquitin system and the N-end rule pathway. Biol Chem. 2000;381:779-789.
20. Bonini C, Lee SP, Riddell SR, et al. Targeting antigen in mature dendritic cells for simultaneous stimulation of CD4+ and CD8+ T cells. J Immunol. 2001;166:5250-5257.
21. Lin KY, Guarnieri FG, Staveley-O'Carroll KF, et al. Treatment of established tumors with a novel vaccine that enhances major histocompatibility class II presentation of tumor antigen. Cancer Res. 1996;56:21-26.
22. Thomson SA, Burrows SR, Misko IS, et al. Targeting a polyepitope protein incorporating multiple class II-restricted viral epitopes to the secretory/endocytic pathway facilitates immune recognition by CD4+ cytotoxic T lymphocytes: a novel approach to vaccine design. J Virol. 1998;72:2246-2252.
23. Wu TC, Guarnieri FG, Staveley-O'Carroll KF, et al., Engineering an intracellular pathway for major histocompatibility complex class II presentation of antigens. Proc Natl Acad Sci USA. 1995;92:11671-11675.
24. Morgan RA, Anderson WF. Human gene therapy. Annu Rev Biochem. 1993;62:191-217.
25. Anderson WF. Human gene therapy. Nature. 1998;392:25-30.
26. Dietz AB, Vuk-Pavlovic S. High efficiency adenovirus-mediated gene transfer to human dendritic cells. Blood. 1998;91:392-398.
27. Robbins PD, Ghivizzani SC. Viral vectors for gene therapy. Pharmacol Ther. 1998;80:35-47.
28. Boczkowski D, Nair SK, Nam JH, et al. Induction of tumor immunity and cytotoxic T lymphocyte responses using dendritic cells transfected with messenger RNA amplified from tumor cells. Cancer Res. 2000;60:1028-1034.
29. Koido S, Kashiwaba M, Chen D, et al. Induction of antitumor immunity by vaccination of dendritic cells transfected with MUC1 RNA. J Immunol. 2000;165:5713-5719.
30. Irvine AS, Trinder PK, Laughton DL et al., Efficient nonviral transfection of dendritic cells and their use for in vivo immunization. Nat Biotechnol. 2000;18:1273-1278.
31. Li S, Huang L. Nonviral gene therapy: promises and challenges. Gene Ther. 2000;7:31-34.
32. Mitchell DA, Nair SK. RNA-transfected dendritic cells in cancer immunotherapy. J Clin Invest. 2000;106:1065-1069.
33. Nair SK, Heiser A, Boczkowski D, et al. Induction of cytotoxic T cell responses and tumor immunity against unrelated tumors using telomerase reverse transcriptase RNA transfected dendritic cells. Nat Med. 2000;6:1011-1017.
34. Strobel I, Berchtold S, Gotze A, et al. Human dendritic cells transfected with either RNA or DNA encoding influenza matrix protein M1 differ in their ability to stimulate cytotoxic T lymphocytes. Gene Ther. 2000;7:2028-2035.
35. Heiser A, Maurice MA, Yancey DR, et al. Human dendritic cells transfected with renal tumor RNA stimulate polyclonal T-cell responses against antigens expressed by primary and metastatic tumors. Cancer Res. 2001;61:3388-3393.
36. Van Tendeloo VF, Ponsaerts P, Lardon F, et al. Highly efficient gene delivery by mRNA electroporation in human hematopoietic cells: superiority to lipofection and passive pulsing of mRNA and to electroporation of plasmid cDNA for tumor antigen loading of dendritic cells. Blood. 2001;98:49-56.
37. Ponsaerts P, Van Tendeloo VF, Cools N, et al. mRNA-electroporated mature dendritic cells retain transgene expression, phenotypical properties and stimulatory capacity after cryopreservation. Leukemia. 2002;16:1324-1330.
38. Kalady MF, Onaitis MW, Padilla KM, et al. Enhanced dendritic cell antigen presentation in RNA-based immunotherapy. J Surg Res. 2002;105:17-24.
39. Tuyaerts S, Noppe M, Corthals J, et al. Generation of large numbers of dendritic cells in a closed system using cell factories. J Immunol Methods. 2002;264:135-151.
40. Boczkowski D, Nair SK, Snyder D, et al. Dendritic cells pulsed with RNA are potent antigen-presenting cells in vitro and in vivo. J Exp Med. 1996;184:465-472.
41. Morel S, Levy F, Burlet-Schiltz O, et al. Processing of some antigens by the standard proteasome but not by the immunoproteasome results in poor presentation by dendritic cells. Immunity. 2000;12:107-117.
42. Van den Eynde BJ, Morel S. Differential processing of class-I-restricted epitopes by the standard proteasome and the immunoproteasome. Curr Opin Immunol. 2001;13:147-153.
43. Ashley DM, Faiola B, Nair S, et al. Bone marrow-generated dendritic cells pulsed with tumor extracts or tumor RNA induce antitumor immunity against central nervous system tumors. J Exp Med. 1997;186:1177-1182.
44. Van Meirvenne S, Straetman L, Heirman C, et al. Efficient genetic modification of murine dendritic cells by electroporation with mRNA. Cancer Gene Ther. 2002;9:787-797.